The information presented on this website is effective as of
January 17, 2022.
PAXLOVID (nirmatrelvir tablets; ritonavir tablets) is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
PAXLOVID is not authorized:
View the full Product Monograph, which includes dosing, clinical data and safety information.
View the full Patient Medication Information, which contains important information for the patient about how to take PAXLOVID and what to expect from treatment.
View the Health Product Risk Communication, which includes a description of the health risk associated with PAXLOVID, what health professionals can do and any other important information.
Call 1-800-463-6001 (Medical Information) or visit pfizermedicalinformation.ca.
Call our customer service line at 1-888-888-9221 or email us at [email protected].
Reporting a Side Effect
We encourage you to visit our designated safety web portal, where you can efficiently and seamlessly report your experience with PAXLOVID. You can access this web portal at www.pfizersafetyreporting.com.
Recipients or their caregivers should contact their healthcare professional if they experience an adverse event after receiving PAXLOVID. Please refer them to the Patient Medication Information.
Call 1-866-9PFIZER (1-866-973-4937) or email [email protected].
This material was developed by Pfizer, as part of the risk minimization plan for PAXLOVID. This material is not intended for promotional use.
This site is intended only for Canadian healthcare professionals. The products discussed in this site may have different product labelling in different countries. The information provided is for educational purposes only.